Subtopic Deep Dive
Rituximab Therapy in IgG4-Related Disease
Research Guide
What is Rituximab Therapy in IgG4-Related Disease?
Rituximab therapy in IgG4-related disease uses B-cell depletion to treat steroid-refractory cases, reducing relapse rates in multiorgan manifestations.
Rituximab provides a steroid-sparing option for IgG4-RD patients unresponsive to glucocorticoids (Khosroshahi et al., 2011, 485 citations). Long-term studies show efficacy in induction and relapse prevention, with frequent relapses after B-cell reconstitution (Ebbo et al., 2017, 238 citations). Over 10 papers from 2011-2017 detail dosing, biomarkers like plasmablasts, and outcomes.
Why It Matters
Rituximab enables management of multiorgan IgG4-RD including pancreas, salivary glands, and retroperitoneum, avoiding steroid toxicities (Khosroshahi et al., 2011). French nationwide data confirm longer relapse-free survival with maintenance infusions (Ebbo et al., 2017). Plasmablast monitoring predicts flares independent of IgG4 levels, guiding therapy (Wallace et al., 2014). Responder indices standardize trial assessments (Carruthers et al., 2012).
Key Research Challenges
Relapse After B-Cell Recovery
Relapses occur frequently post-rituximab as B-cells reconstitute, requiring maintenance dosing (Ebbo et al., 2017). Optimal infusion timing lacks consensus. Plasmablast expansions signal active disease (Mattoo et al., 2014).
Biomarker Validation Beyond IgG4
Serum IgG4 correlates poorly with activity; circulating plasmablasts offer independence but need prospective validation (Wallace et al., 2014). Oligoclonal expansions track relapses (Mattoo et al., 2014). Standardized cutoffs remain undefined.
Long-Term Safety in Multiorgan Disease
Efficacy spans organs but infection risks and rare malignancies need monitoring in large cohorts (Ebbo et al., 2017). Histopathology confirmation varies (Deshpande et al., 2012). Dosing optimization for severe cases unaddressed.
Essential Papers
Consensus statement on the pathology of IgG4-related disease
Vikram Deshpande, Yoh Zen, John K. C. Chan et al. · 2012 · Modern Pathology · 2.5K citations
A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details
Hisanori Umehara, Kazuichi Okazaki, Yasufumi Masaki et al. · 2011 · Modern Rheumatology · 718 citations
IgG4-related disease (IgG4RD) is a novel clinical disease entity characterized by elevated serum IgG4 concentration and tumefaction or tissue infiltration by IgG4-positive plasma cells. IgG4RD may ...
International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease
David C. Fajgenbaum, Thomas S. Uldrick, Adam Bagg et al. · 2017 · Blood · 582 citations
Key Points An international panel established the first ever diagnostic criteria for iMCD based on review of 244 clinical cases and 88 tissue samples. The criteria require multicentric lymphadenopa...
Rituximab for the Treatment of IgG4-Related Disease
Arezou Khosroshahi, Mollie N. Carruthers, Vikram Deshpande et al. · 2011 · Medicine · 485 citations
Patients with IgG4-related disease (IgG4-RD) typically have elevated serum concentrations of IgG4 and share histopathologic features that are similar across affected organ(s). IgG4-RD patients freq...
Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations
Zachary S. Wallace, Hamid Mattoo, Mollie N. Carruthers et al. · 2014 · Annals of the Rheumatic Diseases · 483 citations
Recent Advances in Autoimmune Pancreatitis
Phil A. Hart, Yoh Zen, Suresh T. Chari · 2015 · Gastroenterology · 387 citations
De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease
Hamid Mattoo, Vinay S. Mahajan, Emanuel Della‐Torre et al. · 2014 · Journal of Allergy and Clinical Immunology · 374 citations
Reading Guide
Foundational Papers
Start with Khosroshahi et al. (2011) for initial rituximab evidence, Deshpande et al. (2012) for pathology consensus, Umehara et al. (2011) for IgG4-RD definition.
Recent Advances
Ebbo et al. (2017) for long-term safety; Wallace et al. (2014) and Mattoo et al. (2014) for plasmablast biomarkers.
Core Methods
B-cell depletion via anti-CD20; response via Responder Index (Carruthers 2012); biomarkers include oligoclonal plasmablasts (Mattoo 2014).
How PapersFlow Helps You Research Rituximab Therapy in IgG4-Related Disease
Discover & Search
Research Agent uses searchPapers('rituximab IgG4-RD relapse') to retrieve Khosroshahi et al. (2011), then citationGraph reveals Ebbo et al. (2017) and Wallace et al. (2014); exaSearch uncovers French cohort extensions; findSimilarPapers links to plasmablast biomarkers.
Analyze & Verify
Analysis Agent applies readPaperContent on Ebbo et al. (2017) to extract relapse rates, verifyResponse with CoVe cross-checks against Khosroshahi et al. (2011), runPythonAnalysis computes survival curves from cohort data using pandas; GRADE grades rituximab evidence as moderate for induction.
Synthesize & Write
Synthesis Agent detects gaps in maintenance dosing via contradiction flagging between Ebbo (2017) and Carruthers (2012), Writing Agent uses latexEditText for responder index tables, latexSyncCitations integrates Deshpande (2012), latexCompile generates trial flowcharts, exportMermaid diagrams B-cell depletion pathways.
Use Cases
"Analyze relapse rates and survival in rituximab IgG4-RD cohorts"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas survival curves from Ebbo 2017 data) → researcher gets Kaplan-Meier plots and hazard ratios.
"Draft LaTeX review on rituximab biomarkers in IgG4-RD"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Khosroshahi 2011, Wallace 2014) + latexCompile → researcher gets compiled PDF with cited sections.
"Find code for plasmablast analysis in IgG4 studies"
Research Agent → paperExtractUrls (Wallace 2014) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets flow cytometry R scripts for biomarker gating.
Automated Workflows
Deep Research workflow scans 50+ IgG4-RD papers via searchPapers → citationGraph → structured report on rituximab efficacy with GRADE scores. DeepScan's 7-step chain verifies Ebbo (2017) relapse data against cohorts using CoVe checkpoints. Theorizer generates hypotheses on plasmablast-targeted dosing from Mattoo (2014) expansions.
Frequently Asked Questions
What defines rituximab therapy in IgG4-RD?
Rituximab depletes B-cells in steroid-refractory IgG4-RD, inducing remission across organs (Khosroshahi et al., 2011).
What methods assess rituximab response?
IgG4-RD Responder Index tracks organ scores; plasmablast counts monitor activity (Carruthers et al., 2012; Wallace et al., 2014).
What are key papers on rituximab in IgG4-RD?
Khosroshahi et al. (2011, 485 citations) first reported efficacy; Ebbo et al. (2017, 238 citations) detailed long-term French data.
What open problems exist?
Optimal maintenance dosing, validated non-IgG4 biomarkers, and infection risks need randomized trials.
Research IgG4-Related and Inflammatory Diseases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Rituximab Therapy in IgG4-Related Disease with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers